Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Icosabutate - NorthSea Therapeutics

Next Previous
Drug Profile

Icosabutate - NorthSea Therapeutics

Alternative Names: NST-4016; PRC-4016

Latest Information Update: 14 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pronova BioPharma
  • Developer NorthSea Therapeutics; Pronova BioPharma
  • Class Anti-inflammatories; Antifibrotics; Antihyperlipidaemics; Omega 3 fatty acids; Unsaturated fatty acids
  • Mechanism of Action Cholesterol ester transfer protein inhibitors; FFAR1 protein agonists; GPR120 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dyslipidaemias; Hypertriglyceridaemia; Non-alcoholic steatohepatitis
  • No development reported Hypercholesterolaemia

Most Recent Events

  • 06 Mar 2025 Updated efficacy, and adverse events data from the phase IIb ICONA trial in Non-alcoholic steatohepatitis released by NorthSea Therapeutics
  • 10 Nov 2023 Efficacy and adverse event data from phase IIb ICONA trial in Non-alcoholic steatohepatitis presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
  • 10 Nov 2023 NorthSea Therapeutics intends to pursue a registrational development path for icosabutate in Non-alcoholic steatohepatitis

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top